Trial Profile
A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2021
Price :
$35
*
At a glance
- Drugs Amifampridine (Primary)
- Indications Myasthenia gravis
- Focus Registrational; Therapeutic Use
- Sponsors Catalyst Pharmaceuticals
- 29 Jan 2021 New source identified and integrated European Clinical Trials Database (EudraCT2017-004018-25).
- 10 Aug 2020 According to Catalyst Pharmaceuticals media release, detailed results from this study will be made available in a future scientific forum.
- 11 May 2020 According to Catalyst Pharmaceuticals media release, the company expects to report top-line data from the trial in the third quarter 2020.